Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor.

Acidosis is a hallmark of ischemic stroke and a promising neuroprotective target for preventing neuronal injury. Previously, genetic manipulations showed that blockade of acid-sensing ion channel 1a (ASIC1a)-mediated acidotoxicity could dramatically alleviate the volume of brain infarct and restore neurological function after cerebral ischemia. However, few pharmacological candidates have been identified to exhibit efficacy on ischemic stroke through inhibition of ASIC1a.

The synthesis and luminescence of europium (III) complex based on deprotonated 1-(4-ethyl-4H-thieno[3,2-b]indol-6-yl)-4,4,4-trifluorobutane-1,3-dionate and 1,10-phenanthroline.

A new β-diketone ligand, 1-(4-ethyl-4H-thieno[3,2-b]indol-6-yl)-4,4,4-trifluoro-butane-1,3-dione(HL) was synthesized by four steps reaction (Suzuki-Miyaura cross-coupling, Cadogan cyclization, N-ethylation and Claisen condensation reaction) from 1-(4-bromo-3-nitrophenyl)ethanone and thiophen-2-ylboronic acid. Deprotonated ligand (L(-1)) and 1,10-phenanthroline (phen) coordinated to Eu(3+) to obtain a new europium (III) complex, EuL(3)(phen). The complex was characterized by elementary analysis, IR, (1)H NMR, UV-Visible absorption spectroscopy, thermogravimetric analysis (TGA) and photoluminescence (PL) measurements in detail.